Double depression

Last updated

Double depression refers to the co-existence of major depressive disorder (MDD) and persistent depressive disorder (PDD), the latter previously referred to as dysthymia. Research has shown that double depression tends to be more severe than either MDD or PDD alone and that individuals with double depression experience relapse more often than those with either MDD or PDD alone. [1] [2] However, there is some research that indicates few differences exist between double depression, MDD, and PDD; as a result, those researchers conclude that double depression is not a distinct disorder. [3] [4]

Contents

The literature that details the pharmaceutical treatment of double depression is sparse. Although there are studies that demonstrate that certain medications, such as selective serotonin reuptake inhibitors (SSRIs), are effective methods of treatment, those studies lack placebo controls; therefore, the studies' conclusions are questionable. [5] [6] [7]

Research has found that, as is the case with other depressive disorders, pharmaceutical and therapeutic treatments combined are more effective than the use of either form of treatment alone. [8] Individuals with double depression tend to experience more functional impairment than those with either MDD or PDD alone. [9] As a result, researchers emphasize the need for unique treatments for double depression to be developed and implemented. [10]

Presentation

Individuals with double depression meet the DSM-5 classification criteria for both MDD and PDD. [11] Goldney and Fisher (2004) determined that, in a sample of 3,010 individuals from southern portions of Australia calculated a prevalence rate of double depression of 2.2%. [12] Jonas et al. (2003) reported a prevalence rate of double depression in the United States of 3.4%—based upon an assessment of 7,667 Americans. [13] The prevalence rate of double depression can be compared to rates of PDD at 6.2%, major depressive episode (MDE) at 8.6%, and major depressive episode with severity (MDE-s) at 7.7%. Keller and Shapiro (1982) found that 26% of patients within a sample of 101 met the criteria for both MDD and PDD; however, the aforementioned sample is much smaller—and much more inclined to inaccuracies—than the samples (3,010 and 7,667) described above. [14] Thus, double depression is less common than other forms of depression, but it is still a form of depression that warrants medical attention in the form of behavioral therapies; pharmaceutical treatments; or, both (Miller, Norman, and Keitner, 1999). [8]

The characteristics of those with double depression tend to be more severe in nature than those associated with those who have either MDD or PDD. [15] Levitt, Joffe, and MacDonald (1991) found that those with double depression experience fluctuations in mood at an earlier point in life, a more substantial number of depressive episodes, as well as co-morbid disorders of anxieties more often than their MDD-alone counterparts. [1] Goldney and Fisher (2004) reported that individuals with double depression seek medical attention more often than those with either MDD or PDD alone. [12] Leader and Klein (1996) [9] found that individuals with double depression experience a more substantial level of social impairment, which includes factors such as leisure pursuits and relationship characteristics, than those with either MDD or PDD. Dixon and Thyer (1998) concluded that individuals with double depression experiences recoveries on a more frequent basis than their counterparts who have MDD alone (88% to 69%); however, individuals with double depression experience the most substantial rates of relapse of all of those who suffer from chronic depression. [11] In addition, remission from MDD tends to happen faster than remission from PDD (Dixon & Thyer, 1998). [11]

Miller, Norman, and Dow (1986) reported that individuals with double depression endure a more severe path of illness, but experience few differences with respect to social impairment compared to their MDD-alone counterparts. [3] In addition, McCullough et al. (2000) found that, with the exception that patients with double depression tended to experience of more severe illness, few differences were apparent. [4] Therefore, the conclusions drawn in previous research that are associated with the nature of the clinical presentation of double depression are mixed. Multiple scientists [12] emphasize the need for additional research to determine adequate treatments for those with double depression, as depression is a disease that places a considerable burden upon communities and societies; furthermore, those researchers predict depression will be, in an economic sense, the second-most burdensome disease on societies come 2020.

Treatment

Research on pharmaceutical treatment of double depression in particular is sparse. Certain medications, such as fluoxetine, were found in numerous studies to be effective at reducing symptom severity; however, these studies involved open-label trials, double-blind randomized trials that lack placebo conditions, and small sample sizes. Thus, placebo-controlled trials are needed in order to determine adequate and unique treatments for double depression. In addition, the considerable burden depression places upon communities and societies (Goldney & Fisher, 2004) [12] emphasizes the need for additional research into the treatment of chronic depression.

Hellerstein et al. (1994) theorized that antidepressant medications could be used to ameliorate both MDD and PDD; a pharmaceutical trial found that fluoxetine facilitated remission in 57.1% of patients after five months of treatment. [16] In addition, Miller, Norman, and Keitner (1999) conducted an intervention in which one cohort received pharmaceutical treatment while another cohort received both pharmaceutical and therapeutic treatment. Their results indicated that those who received the combined intervention were more functional—in a social sense—as well as relieved of their depression than those who received the pharmaceutical intervention alone (Miller, Norman, & Keitner, 1999). [8] However, the researchers found that the effect disappeared at both the 6 and 12-month follow-up assessments.

Vasile et al. (2012) conducted a pharmaceutical trial with 16 patients with double depression (who had comorbid alcohol dependence) who were treated and monitored for six months. Results showed that three antidepressants—venlafaxine, duloxetine, and milnacipran—were associated with substantial improvement; venlafaxine was the most effective of the three antidepressants. [17]

Koran, Aboujaoude, and Gamel (2007) conducted a pharmaceutical trial with 24 adults who received duloxetine over the course of a 12-week period. Results showed that duloxetine was successful in the treatment of both PDD as well as double depression. However, the researchers' trial was an open-label trial; as a result, the researchers called for a double-blind and placebo-controlled trial to be conducted in order to further validate the benefits the medication seems to provide. [6]

In addition, Waslick et al. (1999) used duloxetine to treat 19 children and adolescents with either PDD or double depression; after eight weeks of pharmaceutical treatment, 11 of the patients failed to meet the classification criteria for one of the two disorders, which led to the conclusion that duloxetine was a medication that appeared to provide relief from PDD and double depression in children and adolescents. [18] However, the aforementioned trial (in addition to Koran et al.'s (2007) trial) [6] was an open-label trial, which the authors noted as a limitation.

Hirschfield et al. (1998) conducted a 12-week randomized controlled trial (RCT) that involved the administration of sertraline or imipramine, after which 324 of 623 patients either qualified for remission or experienced a substantive improvement in clinical presentation. [5] In a double-blind, fixed-dose trial that involved the use of either the monoamine oxidase inhibitor (MAOI) moclobemide or the selective serotonin reuptake inhibitor (SSRI) fluoxetine, Duarte, Mikkelsen, and DeliniStula (1996) were able to facilitate a minimum of a 50% score reduction on the Hamilton Depression Rating Scale (HDRS). [19] 71% of cases that involved moclobemide—versus 38% of cases that involved fluoxetine—were determined to achieve the aforementioned desired outcome. As a result, the researchers concluded that both antidepressants were similar in their abilities to treat double depression in an effective fashion. However, the lack of a placebo control undermines the extent to which the results can be applied.

Marin, Kocsis, Frances, and Parides (1994) conducted an eight-week open trial that entailed the administration of desipramine to 42 individuals with double depression and 33 individuals with PDD. The researchers found that 70% of the PDD patients experienced a substantial improvement in clinical presentation; the proportion associated with the double depression-cohort was said to be similar. However, the lack of blindness as well as a placebo control notes a considerable limitation of the aforementioned research. [7]

Goldney and Bain (2006) found that those who have double depression receive some form of treatment on a more substantial basis than their MDD-alone and PDD-alone counterparts. To elaborate, the authors measured that, in Australia, 41.4% of those evaluated with double depression received treatment three or more times over the course of the previous month, whereas 34.5% of those with MDD alone; 23.2% of those with PDD alone; and 10.3% of those who were not depressed received treatment three or more times over the course of the previous month (Goldney & Bain, 2006). [20] In addition, the researchers concluded that those with double depression acquire a more substantial number of treatment visits per month (a mean of 4.3) when compared to their MDD-alone counterparts (a mean of 3.0); their PDD-alone counterparts (a mean of 2.6); and their non-depressed counterparts (a mean of 1.5).

Prognosis

Although double depression is less prevalent than either MDD or PDD, [12] [13] it is still a form of depression that warrants medical attention in the form of behavioral therapies; pharmaceutical treatments; or, both. [8] Miller, Norman, and Keitner (1999) found that the use of both behavioral and pharmaceutical treatments was more effective on a short-term basis in the reduction of depression than the use of pharmaceutical treatments alone. [8]

Klein, Shankman, and Rose (2008) determined that poor maternal-child relationship, histories of sexual abuse, co-morbid disorders of anxieties, and lower educational attainment predicted an increased HAM-D score after a decade; the researchers also determined that those same factors predicted, after a decade, increased functional impairment. In addition, the results showed that the life course of depression did not differ to a substantial extent between individuals with MDD-alone and double depression. [10]

Hirschfield et al. (1998) conducted a 12-week RCT that involved the administration of sertraline or imipramine, in which the most notable predictors of treatment response were educational attainment and relationship status; in addition, the authors noted the apparent influence of intrinsic personal traits. However, Hirschfield et al. noted the limitation of a lack of a placebo control. [5]

Klein, Taylor, Harding, and Dickstein (1988) reported that, via their assessment of clinical, familial, and socio-environmental characteristics of those with chronic depression, at a six-month follow-up, individuals with double depression experienced decreased rates of remission, increased manifestations of clinical depressive phenomena, increased functional impairment, and increased likelihood of the development and onset of a hypomanic episode than their MDD-alone counterparts; as a result, the authors underscore the importance of the creation of a distinct classification of double depression due to its unique episodic path. [21]

Controversies

Previous research on the clinical presentation of double depression tends to be mixed. Numerous studies indicate that the course of double depression tends to be more severe in nature. [2] [1] [4] [3] In addition, numerous studies demonstrate that individuals with double depression seek medical attention to a more substantial extent than those with either MDD or PDD. [20] [12] However, Miller, Norman, and Dow (1986) determined that individuals with MDD or PDD versus individuals with double depression experienced similar levels of social impairment. In addition, McCullough and colleagues found that there were few additional differences overall between the characteristics of those with double depression versus those with either MDD or PDD. [3]

Research on the course of double depression is also mixed. Klein, Taylor, Harding, and Dickstein (1988) found that remission in individuals with double depression is less probable than it is in individuals with either MDD or PDD; the researchers also noted that those with double depression are more prone to the development and onset of a hypomanic episode than those with either MDD or PDD. [21] In addition, Klein, Shankman, and Rose (2008) and Hirschfield et al. (1998) both concluded that educational status predicted treatment outcome. [5] [10] However, Levitt, Joffe, and MacDonald (1991) demonstrated that the courses of the respective depressive disorders did not differ to a substantial extent. [1] While Klein, Shankman, and Rose (2008) advocate for the creation of a distinct classification of double depression in the future edition(s) of the DSM, [10] Levitt and colleagues (as well as McCullough and colleagues) seem to indicate that, due to the numerous similarities as well as limited differences between double depression and either MDD or PDD, the creation of such a classification would be inappropriate and incorrect. Remick, Sadovnick, Lam, Zis, and Yee (1996) determine that the heritable bases of MDD, PDD, and double depression are similar and that, as a result, the three disorders are unable to be differentiated. [22]

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The efficacy of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). However, for OCD, cognitive behavioral therapy, particularly in combination with sertraline, is a better treatment. Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Duloxetine</span> Antidepressant medication used also for treatment of anxiety and chronic pain

Duloxetine, sold under the brand name Cymbalta among others, is a medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic pain and central sensitization. It is taken by mouth.

<span class="mw-page-title-main">Serotonin–norepinephrine reuptake inhibitor</span> Class of antidepressant medication

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, obsessive–compulsive disorder (OCD), social phobia, attention-deficit hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters.

<span class="mw-page-title-main">Generalized anxiety disorder</span> Long-lasting anxiety not focused on any one object or situation

Generalized anxiety disorder (GAD) is a mental and behavioral disorder, specifically an anxiety disorder characterized by excessive, uncontrollable and often irrational worry about events or activities. Worry often interferes with daily functioning, and individuals with GAD are often overly concerned about everyday matters such as health, finances, death, family, relationship concerns, or work difficulties. Symptoms may include excessive worry, restlessness, trouble sleeping, exhaustion, irritability, sweating, and trembling.

Dysthymia, also known as persistent depressive disorder (PDD), is a mental and behavioral disorder, specifically a disorder primarily of mood, consisting of similar cognitive and physical problems as major depressive disorder, but with longer-lasting symptoms. The concept was used by Robert Spitzer as a replacement for the term "depressive personality" in the late 1970s.

<span class="mw-page-title-main">Psychotic depression</span> Medical condition

Psychotic depression, also known as depressive psychosis, is a major depressive episode that is accompanied by psychotic symptoms. It can occur in the context of bipolar disorder or major depressive disorder. It can be difficult to distinguish from schizoaffective disorder, a diagnosis that requires the presence of psychotic symptoms for at least two weeks without any mood symptoms present. Unipolar psychotic depression requires that psychotic symptoms occur during severe depressive episodes, although residual psychotic symptoms may also be present in between episodes. Diagnosis using the DSM-5 involves meeting the criteria for a major depressive episode, along with the criteria for "mood-congruent or mood-incongruent psychotic features" specifier.

Treatment-resistant depression is a term used in psychiatry to describe people with major depressive disorder (MDD) who do not respond adequately to a course of appropriate antidepressant medication within a certain time. Definitions of treatment-resistant depression vary, and they do not include a resistance to psychological therapies. Inadequate response has most commonly been defined as less than 50% reduction in depressive symptoms following treatment with at least one antidepressant medication, although definitions vary widely. Some other factors that may contribute to inadequate treatment are: a history of repeated or severe adverse childhood experiences, early discontinuation of treatment, insufficient dosage of medication, patient noncompliance, misdiagnosis, cognitive impairment, low income and other socio-economic variables, and concurrent medical conditions, including comorbid psychiatric disorders. Cases of treatment-resistant depression may also be referred to by which medications people with treatment-resistant depression are resistant to. In treatment-resistant depression adding further treatments such as psychotherapy, lithium, or aripiprazole is weakly supported as of 2019.

<span class="mw-page-title-main">Agomelatine</span> Atypical antidepressant classified primarily as a melatonin receptor agonist

Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.

<span class="mw-page-title-main">Olanzapine/fluoxetine</span> Antidepressant medication

Olanzapine/fluoxetine is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.

<span class="mw-page-title-main">Fluoxetine</span> SSRI antidepressant

Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), anxiety, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is also approved for treatment of major depressive disorder in adolescents and children 8 years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.

<span class="mw-page-title-main">Esketamine</span> Medication

Esketamine, also known as (S)-ketamine or S(+)-ketamine, is the S(+) enantiomer of ketamine. It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression. It is sold under the brand names Spravato, Ketanest, among others. Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine.

The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries.

Minor depressive disorder, also known as minor depression, is a mood disorder that does not meet the full criteria for major depressive disorder but at least two depressive symptoms are present for a long time. These symptoms can be seen in many different psychiatric and mental disorders, which can lead to more specific diagnoses of an individual's condition. However, some of the situations might not fall under specific categories listed in the Diagnostic and Statistical Manual of Mental Disorders. Minor depressive disorder is an example of one of these nonspecific diagnoses, as it is a disorder classified in the DSM-IV-TR under the category Depressive Disorder Not Otherwise Specified (DD-NOS). The classification of NOS depressive disorders is up for debate. Minor depressive disorder as a term was never an officially accepted term, but was listed in Appendix B of the DSM-IV-TR. This is the only version of the DSM that contains the term, as the prior versions and the most recent edition, DSM-5, does not mention it.

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

<span class="mw-page-title-main">NSI-189</span> Chemical compound

NSI-189 is an experimental, potential antidepressant that was developed by Neuralstem, Inc. for the treatment for major depressive disorder (MDD), as well as for cognitive impairment and neurodegeneration.

Aripiprazole/sertraline is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.

<span class="mw-page-title-main">Dextromethorphan/bupropion</span> Combination medication

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). Its active components are dextromethorphan (DXM) and bupropion. Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. It is taken as a tablet by mouth.

<span class="mw-page-title-main">Zuranolone</span> Chemical compound

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. It is taken by mouth.

References

  1. 1 2 3 4 Levitt, A.; Joffe, R.; MacDonald, C. (1991). "Life course of depressive-illness and characteristics of current episode in patients with double depression". Journal of Nervous and Mental Disease. 179 (11): 678–682. doi:10.1097/00005053-199111000-00005. PMID   1940891.
  2. 1 2 Joiner, T.; Cook, J.; Hersen, M.; Gordon, K. (2007). "Double depression in older adult psychiatric outpatients: Hopelessness as a defining feature". Journal of Affective Disorders. 101 (1–3): 235–238. doi:10.1016/j.jad.2005.03.019. PMID   17475340.
  3. 1 2 3 4 Miller, I.; Norman, W.; Dow, M. (1986). "Psychosocial characteristics of "double depression". The American Journal of Psychiatry. 143 (8): 1042–1044. doi:10.1176/ajp.143.8.1042. PMID   3728722.
  4. 1 2 3 McCullough, J.; Klein, D.; Keller, M.; Holzer, C.; Davis, S.; Kornstein, S.; Harrison, W. (2000). "Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (Double depression): Validity of the distinction". Journal of Abnormal Psychology. 109 (3): 419–427. doi:10.1037/0021-843X.109.3.419.
  5. 1 2 3 4 Hirschfeld, Robert M. A.; Russell, James M.; Delgado, Pedro L.; Fawcett, Jan; Friedman, Richard A.; Harrison, Wilma M.; Koran, Lorrin M.; Miller, Ivan W.; Thase, Michael E.; Howland, Robert H.; Connolly, Margaret A.; Miceli, Robert J. (1998). "Predictors of Response to Acute Treatment of Chronic and Double Depression with Sertraline or Imipramine". The Journal of Clinical Psychiatry. 59 (12): 669–675. doi:10.4088/JCP.v59n1205. PMID   9921701.
  6. 1 2 3 Koran, Lorrin M.; Aboujaoude, Elias N.; Gamel, Nona N. (2007). "Duloxetine Treatment of Dysthymia and Double Depression". The Journal of Clinical Psychiatry. 68 (5): 761–765. doi:10.4088/JCP.v68n0514. PMID   17503986.
  7. 1 2 Marin, D.; Kocsis, J.; Frances, A.; Parides, M. (1994). "Desipramine for the treatment of "pure" dysthymia versus "double" depression". American Journal of Psychiatry. 151 (7): 1079–1080. doi:10.1176/ajp.151.7.1079. PMID   8010368.
  8. 1 2 3 4 5 Miller, Ivan W.; Norman, William H.; Keitner, Gabor I. (1999). "Combined Treatment for Patients with Double Depression". Psychotherapy and Psychosomatics. 68 (4): 180–185. doi:10.1159/000012330. PMID   10396008. S2CID   483107.
  9. 1 2 Leader, Julie B.; Klein, Daniel N. (1996). "Social adjustment in dysthymia, double depression and episodic major depression". Journal of Affective Disorders. 37 (2–3): 91–101. doi:10.1016/0165-0327(95)00076-3. PMID   8731071.
  10. 1 2 3 4 Klein, Daniel N.; Shankman, Stewart A.; Rose, Suzanne (2008). "Dysthymic disorder and double depression: Prediction of 10-year course trajectories and outcomes". Journal of Psychiatric Research. 42 (5): 408–415. doi:10.1016/j.jpsychires.2007.01.009. PMC   2276359 . PMID   17466334.
  11. 1 2 3 Dixon, Danny R.; Thyer, Bruce A. (1998). "Double Depression in Men: Does It Exist?". Journal of Psychopathology and Behavioral Assessment. 20 (2): 187–198. doi:10.1023/A:1023030431552. S2CID   141425236.
  12. 1 2 3 4 5 6 Goldney, Robert D.; Fisher, Laura J. (2004). "Double depression in an Australian population". Social Psychiatry and Psychiatric Epidemiology. 39 (11): 921–926. doi:10.1007/s00127-004-0832-7. PMID   15549246. S2CID   7864016.
  13. 1 2 Jonas, Bruce S.; Brody, Debra; Roper, Margaret; Narrow, William E. (2003). "Prevalence of mood disorders in a national sample of young American adults". Social Psychiatry and Psychiatric Epidemiology. 38 (11): 618–624. doi:10.1007/s00127-003-0682-8. PMID   14614549. S2CID   22591288.
  14. ↑ Keller, M.; Shapiro, R (1982). ""Double depression": Superimposition of acute depressive episodes on chronic depressive disorders". American Journal of Psychiatry. 139 (4): 438–442. doi:10.1176/ajp.139.4.438. PMID   7065289.
  15. ↑ Joiner, Thomas E.; Cook, Joan M.; Hersen, Michel; Gordon, Kathryn H. (2007). "Double depression in older adult psychiatric outpatients: Hopelessness as a defining feature". Journal of Affective Disorders. 101 (1–3): 235–238. doi:10.1016/j.jad.2005.03.019. PMID   17475340.
  16. ↑ Hellerstein, David J.; Yanowitch, Philip; Rosenthal, Jesse; Hemlock, Camille; Kasch, Karén; Samstag, Lisa Wallner; Winston, Arnold (1994). "Long-term treatment of double depression: A preliminary study with serotonergic antidepressants". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 18 (1): 139–147. doi:10.1016/0278-5846(94)90030-2. PMID   8115668. S2CID   6258169.
  17. ↑ Vasile, D.; Vasiliu, O.; Mangalagiu, A.G.; Banica, A.; Taina, N.F.; Blandu, M. (2012). "P-537 - Comparative analysis of dual serotonergic and noradrenergic antidepressants in double depression with alcohol dependence". European Psychiatry. 27: 1. doi:10.1016/S0924-9338(12)74704-1.
  18. ↑ Waslick, Bruce D.; Walsh, B.Timothy; Greenhill, Laurence L.; Eilenberg, Mara; Capasso, Lisa; Lieber, Danna (1999). "Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression". Journal of Affective Disorders. 56 (2–3): 227–236. doi: 10.1016/S0165-0327(99)00032-4 . PMID   10701482.
  19. ↑ Duarte, Antonio; Mikkelsen, Hans; Delini-Stula, Alexandra (1996). "Moclobemide versus fluoxetine for double depression: A randomized double-blind study". Journal of Psychiatric Research. 30 (6): 453–458. doi:10.1016/S0022-3956(96)00030-1. PMID   9023788.
  20. 1 2 Goldney, Robert D.; Bain, Marcus A. (2006). "Double depression: its morbidity and management in a community setting". Acta Neuropsychiatrica. 18 (5): 210–215. doi:10.1111/j.1601-5215.2006.00153.x. PMID   26989920.
  21. 1 2 Klein, D. N.; Taylor, E. B.; Harding, K.; Dickstein, S. (1988). "Double depression and episodic major depression: Demographic, clinical, familial, personality, and socioenvironmental characteristics and short- term outcome". American Journal of Psychiatry. 145 (10): 1226–1231. doi:10.1176/ajp.145.10.1226. PMID   3421343.
  22. ↑ Remick, R. A.; Sadovnick, A. D.; Lam, R. W.; Zis, A. P.; Yee, I. M. L. (1996). "Major depression, minor depression, and double depression: Are they distinct clinical entities?". American Journal of Medical Genetics. 67 (4): 347–353. doi:10.1002/(SICI)1096-8628(19960726)67:4<347::AID-AJMG6>3.0.CO;2-J. PMID   8837701.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.